 Irritable bowel syndrome (IBS) is a complex condition with multiple factors contributing to its aetiology and pathophysiology, resulting to date in no specific reliable biomarker being identified.
Introduction
Irritable bowel syndrome (IBS) is a common chronic condition with substantial economic and social implications. It accounts for a considerable demand on health care resources worldwide 1 . A recent meta-analysis reported a pooled IBS prevalence of 11.2%, albeit with large differences between individual studies with figures ranging from 1.1 to 45.0% 2 . This may represent true differences related to demographic factors, but comparison is difficult due to the application of different diagnostic criteria and differences in patient selection. Moreover, differences in access to health care and cultural factors, such as help seeking behaviour 3 , may contribute.
IBS is characterized by abdominal pain or discomfort associated with changes in bowel habits, often accompanied by distension and/or bloating 4 . The pathophysiological mechanisms are not fully understood, but a range of different predisposing, precipitating or perpetuating factors may contribute through both central and peripheral mechanisms 1 . Psychological co-morbidity 5, 6 , differences in central processing, genetic factors, visceral hypersensitivity, abnormal gastrointestinal motility and secretion 7 , lowgrade inflammation and alterations in gut microbiota have all been proposed to underlie the diverse spectrum of symptoms reported by IBS patients 8, 9 . Furthermore, dietary factors and food intake, especially the impact of fermentable oligo-, di-, and poly-saccharides and polyols (FODMAP) and gluten has gained much attention lately 10, 11 . Taken together, IBS is a heterogeneous condition with a variety of different pathophysiological mechanisms, obviously requiring a tailored and pathophysiologybased approach to clinical management. However, although the latter is a very appealing concept, it requires the identification of biomarkers, a challenge that so far has not been solved.
To date, mainly due to a lack of objective diagnostic measures, the diagnosis of IBS is still based on symptoms, as defined currently by the Rome III criteria 4 and forthcoming Rome IV criteria. Although this represents an important tool to standardize IBS diagnosis and decreases the heterogeneity of patient populations within clinical trials or translational research, the lack of biomarkers makes it difficult to uniformly define patients. Hence, there is a pressing need to establish a set of tools that can be applied to a large set of patients to phenotype and characterize different subpopulations as accurately and consistently as possible. These tools should be widely applicable and feasible in different settings, allowing valid comparisons of findings from different centres. Ideally the collected data should be combined in large databases. This is essential in order to garner insight into genetics, epigenetics, microbiota and other potential disease modifiers, which in turn will aid further research and improve tailoring of treatment and health care for patients.
The aim of this paper is to discuss the requirements to standardize the process of selecting and phenotyping IBS patients and how to organize the collection and storage of patient information/samples. The proposed approach and documents selected is the result of a thoughtful and thorough discussion amongst experts as part of the European COST Action BM1106 GENIEUR (www.GENIEUR.eu).
The need for further phenotyping IBS patients
As mentioned earlier, the underlying pathophysiology and the clinical presentation of IBS are extremely diverse. Yet, hitherto the classification of IBS patients is limited to differences in defecation pattern yielding four different subgroups or phenotypes, i.e.
IBS with constipation, IBS with diarrhea, mixed IBS and un-subtyped IBS 4 . Clearly, this approach has contributed to improved and differential clinical management, yet the heterogeneity within these subpopulations remains tremendous. Especially for epi-/genetic, microbiota and pathophysiological studies, patients should be better stratified and factors influencing the phenotype, such as diet, psychological co-morbidity and many others should be inventoried in more detail to achieve a homogeneous 
Standardization of data and sample collection
Standardization of data and sample collection holds many challenges, mostly due to differences in the tools used to collect information or the standard procedures used to collect samples or perform/interpret physiological tests. For instance, the manner in which blood, tissue and stool is sampled for epi-/genetics and microbiota analysis, their short and long term storage, shipping conditions has clearly to be defined in order to preserve the material, prevent degradation and bacterial growth which may impair molecular analysis and bias the study outcome. Furthermore, it is of utmost importance that the information to be collected from a large population is well defined and agreed upon prior to the implementation of a study protocol, not only to standardize the process of data collection, but also to prevent collection of unnecessary information.
Moreover, data should be collected and registered in a standardized case report form, constructed in such a way that information can be entered easily and stored in a uniform format in a database. The latter requires the use of checkboxes and pick lists rather than free text. As not all centres will have the financial or logistic means to perform all tests or collect the entire data set, a minimal set of information and samples that must be collected in all patients needs to be determined. This information should consist of demographics, general clinical information, ethnicity, diet, standardized questionnaires related to functional gastrointestinal disorders and IBS, psychological co-morbidity, blood samples and faecal samples (see below). Relevant information that cannot be collected at all sites should be streamlined in different "modules" that are performed or collected in a restricted number of centres with the respective expertise. Detailed assessment of dietary intake, collection of biopsies for assessment of permeability, immunohistochemistry, molecular biological testing, measurement of visceral sensitivity (barostat), gastrointestinal transit or even functional brain imaging are not established in every centre, time consuming and expensive and thus will be restricted to centres of expertise. Nevertheless, standardisation with pooling of the acquired information at the different centres will contribute to more in depth phenotyping in a subpopulation.
General information: demographics, ethnicity, diet and others
Inevitably, general information such as demographics, including date of birth, gender, ethnical background, BMI, education and profession needs to be collected from all subjects as these factors are known to influence the occurrence of symptoms or their reporting 2 . Special attention should be paid to ethnicity as this represents a major determinant in genetic studies 12 . Similarly, family aggregation should be recorded, as the incidence of IBS in siblings and twins is increased 13, 14 , providing valuable information to identify new genetic factors in a family/twin study design. . The BSFS is recommended by the Rome committees and also validated in several European languages 21, 22 . Finally, although IBS is a symptom-based diagnosis, a minimal set of diagnostic tests should be included to exclude confounding organic conditions. A blood test excluding anaemia and inflammation (C-reactive protein) is therefore mandatory. Moreover, conditions mimicking IBS (especially IBS with diarrhea), like lactose malabsorption and celiac disease should ideally be ruled out. Many gastroenterologists perform a lower digestive endoscopy to exclude organic disease, but in the absence of alarm signs, the decision to perform colonoscopy with biopsies remains at the discretion of the individual practitioner 23 . Functional tests (see below) are optional according to the availability in different centres.
Last but not least, standardized criteria have to be defined to select controls. Healthy controls should be subjects with no gastrointestinal symptoms, as assessed by the questionnaires used (see below), and no chronic disorders that may affect research outcomes.
All data recommend to be collected for IBS phenotyping can be retrieved from the following website: www.GENIEUR.eu. questionnaire may also be subdivided into modules for the purpose of focusing on a specific (group of) FGID(s) (e.g. functional bowel disorders) rather than all FGIDs, depending on the research question. This questionnaire is also valid for use in control subjects participating in research studies in order to exclude FGIDs, which is important as GI symptoms are very common in the community 26 .
GI symptom assessment
A similar questionnaire will be available for the Rome IV criteria when these are published.
Assessment of IBS symptom pattern & severity
Besides confirming the diagnosis of IBS and other FGIDs, it is also of importance to assess the overall severity of IBS, as well as the severity and pattern of different IBS symptoms. Amongst several others, the two most widely used questionnaires are the IBS severity scoring system (IBS-SSS) 27 , and the Gastrointestinal Symptom Rating Scale (GSRS) 28 , which has also been developed into an IBS-specific version (GSRS-IBS). Moreover, as retrospective assessment of bowel habit and IBS subtyping, which is based on stool consistency, seems to be unreliable 29 , a prospective bowel habit diary using the validated Bristol Stool Form Scale (BSFS) is often advocated 30, 31 .
IBS Severity Scoring System (IBS-SSS)
The IBS Severity Scoring System (IBS-SSS) was developed as a simple, easy to use scoring system for IBS in order to reliably capture effects of treatments and or other interventions 27 . It has undergone sufficient validation, and has also been used extensively as an outcome measure in trials assessing different treatment options for IBS 17, 32, 33 . The questionnaire includes five items; abdominal pain intensity, abdominal pain frequency, abdominal distension, dissatisfaction with bowel habits, influence of IBS on life in general ("life interference"); each scored 0-100. All of the questions use visual analogue scales (0-100), except for the abdominal pain frequency question, which collects the number of pain days during the previous 10 days with the response multiplied by 10 to obtain a score between 0 and 100. The total IBS-SSS score thus has a range from between 0 to 500, with higher scores indicating more severe symptoms. Frequently accepted cut-off levels are used to divide patients into severity groups: <175, mild IBS; 175-300, moderate IBS; >300, severe IBS. In treatment trials a reduction of IBS-SSS total score of 50 has been found to reliably reflect a clinically meaningful improvement 27 .
Gastrointestinal Symptom Rating Scale (GSRS)
The Gastrointestinal Symptom Rating Scale (GSRS) was originally developed as an interview-based rating scale to evaluate common symptoms in patients with IBS and peptic ulcer disease 28 , but was later modified to become a self-administered questionnaire 34 . The GSRS has 15 items, each scored using a 7-point Likert scale (1-7), combined into five domains (reflux, indigestion, diarrhea, constipation and abdominal pain) identified through factor analysis 35 . The higher the scores the more severe are the symptoms. A more recent development is the GSRS-IBS, the IBSspecific version of the GSRS 36 . This 13-item questionnaire determines the pattern and severity of IBS-related symptoms during the past week using a similar 7-point Likert scale with descriptive anchors as the original GSRS (ranging from "no discomfort" to "very severe discomfort"). The items are divided into five domains: pain, bloating, constipation, diarrhea, and satiety. One advantage with GSRS and GSRS-IBS relative to IBS-SSS for use in large-scale IBS studies is that they also include questions about upper GI symptoms, which is relevant for careful phenotyping. Moreover, with the GSRS and GSRS-IBS it is possible to separately determine the perceived severity of diarrhea and constipation, which is not possible with IBS-SSS, as this questionnaire only asks for dissatisfaction with bowel habits in general.
Bristol Stool Form Scale
IBS subgrouping is based on stool consistency defined by the widely used Bristol Stool Form Scale (BSFS) 4 . This is a 7-point scale to describe the stool consistency; 1, separate hard lumps like nuts; 2, sausage shaped but lumpy; 3, like a sausage or snake but with cracks on its surface; 4, like a sausage or snake, smooth and soft; 5, soft blobs with clear cut edges; 6, fluffy pieces with ragged edges, a mushy stool; 7, watery, no solid pieces. The use of the BSFS in bowel habit diaries has been found to be a useful guide to assess intestinal transit time 30, 31 . In IBS trials a one-or two-week bowel habit diary is a useful way to objectively define bowel habit (stool frequency and consistency) and to determine the IBS subgroup 29 . Moreover, it serves as a complement to assessment of the perceived severity of the abnormal bowel habit, as measured with IBS-SSS and/or GSRS-IBS.
Assessment of functional dyspepsia
The rationale for including a psychometric instrument to measure dyspepsia symptom severity in an IBS cohort is the frequent co-morbidity of functional dyspepsia (FD) in IBS. This is not only the case in healthcare seeking patients 37 , but also in the general population 38 . ranging from 0 (not at all) to 4 (extremely), subscales are calculated as an unweighted sum of the 2 underlying items, and a total score can also be calculated by adding up the subscale scores 43 . Both parts of the SF-NDI have good internal consistency, convergent and discriminant validity, and are responsive to change 42, 43 . More recently, minimum clinically important differences have been established 44 . The SF-NDI has been extensively used in FD research and has been translated and validated in many languages.
Assessment of psychological distress and somatic symptom severity ("somatization")
The rationale for including instruments to measure presence and severity of depressive and anxiety disorders, as well as (extra-intestinal) somatic symptom severity ("somatization") lies in the observation that IBS patients have elevated levels of anxiety and depression symptoms, as well as of extra-gastrointestinal bodily symptoms including co-morbidity with anxiety, depressive 45 and somatoform/somatic symptom disorders 6, 46, 47 . Furthermore, higher levels of anxiety, depressive, and extraintestinal somatic symptoms have been shown to be associated with higher levels of impairment in IBS and treatment responses are associated with improvements in anxiety, depression and somatization 48, 49 .
Patient Health Questionnaire (PHQ)
The 
Depression module (PHQ-9)
The PHQ-9 consists of 9 depressive symptom items based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for major depressive episode 54, 55 ; the frequency of each is rated over the prior 2 weeks on a Likert scale ranging from 0 (not at all) to 3 (almost every day). The total score can be used as a continuous measure of depressive symptom severity ranging from 0 to 27 or, alternatively, cut-off points of 5, 10, 15, and 20 can be used representing mild, moderate, moderately severe, and severe levels of depressive symptoms. The presence of depressive disorder can be determined using a DSM-IV based diagnostic algorithm, or an optimal cut-off point ≥10 (with the latter performing better in terms of sensitivity) 50, 56, 57 .
Anxiety Module (GAD-7)
The GAD-7 consists of 7 anxiety symptoms based on DSM-IV criteria for generalized anxiety disorder 55, 58 , which are scored as in the PHQ-9, and can be summed up to generate a continuous anxiety severity score ranging from 0-21, with 5, 10, and 15
representing cut-off points for mild, moderate, and severe levels of anxiety symptoms, respectively. In a manner similar to the PHQ-9, ≥10 represents the optimal cut-off point for "caseness", in this case for generalized anxiety disorder. However, although it was originally developed as an instrument to detect generalized anxiety disorder, the GAD-7 was also shown to have good sensitivity and specificity (at the same cut-off point of ≥10) as a screening tool for panic, social anxiety, and post-traumatic stress disorder 50 , which are also frequently co-morbid with IBS.
Somatic Symptom Severity ("Somatization") module (PHQ-15)
The PHQ-15 consists of 15 somatic symptom items that account for more than 90% of symptoms seen in primary care, and which also constitute the diagnostic criteria for the now abandoned DSM-IV category of somatization disorder 55, [59] [60] [61] . Subjects rate how much they have been bothered by each symptom during the past month on a Likert scale ranging from 0 ("not at all") to 2 ("bothered a lot"). The total (sum) score thus ranges from 0 to 30, with cut-off points of 5, 10, and 15 representing thresholds for mild, moderate, and severe somatic symptom severity, respectively. As the PHQ-15 included 3 GI symptom items ("stomach pain", "constipation, loose bowels, or diarrhea", and "nausea, gas, or indigestion"), one of which constitutes a core IBS symptom, it is recommended to omit these three items when calculating the total score if the aim is to distinguish GI symptom severity from extra-intestinal symptom severity, or test relationships between both. This reduced version (PHQ-12) has been used and validated in IBS patients by Spiller and colleagues 62 .
It should be noted that the PHQ-15 does not provide information on the medically unexplained nature of the somatic symptoms included, nor any data regarding any putative underlying psychological mechanism driving (or resulting from) symptom reporting, two aspects that are central to some, primarily older, conceptualizations of "somatization" 50, 61, 63 . However, the first limitation can be overcome by quantifying psychological distress (anxiety, depression) using the two other PHQ modules discussed above.
Visceral Sensitivity Index (VSI)
Contrary to what may be suggested by the name, this instrument measures gastrointestinal symptom-specific anxiety (GSA), which can be defined as "anxiety related to gastrointestinal sensations, symptoms or the contexts in which these may occur" 64 . It covers 5 dimensions of GI-related cognitions and behaviours; worry, fear, vigilance, sensitivity and avoidance. The rationale to include this instrument in addition to an instrument measuring anxiety in general, lies in the findings that GSA has been shown to be more strongly associated with IBS symptom severity 64 .
The VSI is the only validated instrument to measure GSA, with good psychometric properties consisting of 15 statements, each of which is scored on a 6-point Likert scale ranging from 1 (strongly agree) to 6 (strongly disagree). The items are summed up and the sum is subtracted from 90 to yield a single total score ranging from 0-75, with higher scores representing higher levels of GSA.
Assessment of disease-specific quality of Life
IBS has a profound impact on quality of life 
In depth functional / physiological phenotyping
To establish intermediate phenotypes it is important to correlate symptoms and psychological profiling with physiological characteristics, gut microbiota analysis, and studies of gut tissue for immune and permeability assessment. Homogenous subgroups identified through this approach are more likely to yield meaningful results from genetic and epigenetic studies. The methods for performing such assessments has to be evidence based so that they can then be adopted across multiple collaborating centres to develop large data sets. Herein we discuss the methods for physiological, gut microbiota, blood and tissue sampling studies.
Physiological testing
The primary aim of testing physiological function within IBS is to differentiate normal from abnormal and to correlate pathophysiology with clinical symptomatology.
However, given the current challenges inherent in the pathophysiologic and symptomatic heterogeneity of patients with IBS, current techniques do not have the prerequisite receiver operator characteristics for routine clinical practice. Arguably, this is a consequence of the current manner in which these techniques are evaluated such that they are tested on a relatively small number of IBS patients and are not standardised across different centres. Thus, a standardised approach is required which will not only lead to the generation of large sample sizes of IBS patients, which have hitherto been impossible, but also facilitate the examination of differences in such testing between the different IBS subtypes.
Following detailed literature review and consensus, protocols have been developed (see www.GENIEUR.eu), in order to standardize research activities on IBS physiological testing (visceral sensitivity and permeability studies), taking into account regulations and ethical requirements, both locally and nationally. In addition, the protocols have been designed such that non-specialist, i.e. non-tertiary centres, may also readily contribute to the cohort.
Visceral sensitivity testing -rectal barostat
Mechanical distension of the distal colon can be undertaken to evaluate visceral perception and sensitivity in IBS with previous reports suggesting that up to 60% of patients have heightened sensitivity to distension compared with healthy controls 71, 72 Moreover, visceral hypersensitivity has been proposed as a biomarker in IBS, although it lacks sufficient discriminate sensitivity for routine clinical practice. Although studies have used rectal, sigmoid, and colonic distension, rectal distension has become the "site of choice" as it is more accessible and thus technically more straightforward and only small perceptive differences have been shown between centres
73
.
Rectal sensitivity can be evaluated by utilizing a distensible polyethylene bag placed in the rectum in conjunction with a barostat, a device that maintains a constant pressure within the aforementioned bag. The barostat can delineate changes in the tone of the rectal wall by measuring alterations in volume and pressure within the bag.
During rectal distension, verbal rating scales are used to measure the quality and intensity of pain perception during rising intra-rectal pressure and volume. Rectal distension performed according to specific protocols, during which different pressures are applied to the rectal wall. Although several distension protocols have been used, rapid rectal distension using the ascending method of limits (AML) and random phasic distension (RPD) protocols, are considered to be the most reproducible within individuals and across study centres
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. However, AML and RPD protocols take up to 60 minutes to perform. This approach is therefore not widely practical within routine clinical practice and frequently is not undertaken outside the research environment.
Sauter et al. have recently proposed and validated a rapid barostat bag (RBB)
technique which is as a viable alternative to formal barostat testing in centres where this is not practical
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. Briefly, for RBB a barostat bag is inflated inside the rectum manually via a dual-channel barostat catheter using a syringe with intra-bag filling pressure monitored and recorded by a handheld pressure gauge. After a 'conditioning' inflation a second "index" inflation is performed. Threshold volumes for rectal filling sensations are recorded during the second, index distension using a validated visual analogue scale (i.e. first perception, urgency, discomfort / pain) also used during conventional barostat studies. Alternatively, a shortened distension protocol can be used, in which only three or four distension steps above minimal distension pressure are applied either in an increasing 76, 77 or random fashion 74, 78 . Categorizing patients as hypersensitive, normosensitive or indeed hyposensitive somewhat depends on the distension protocol and normal reference range used, but comparable pain thresholds for hypersensitivity have been described using both the shortened distension protocol (≤21mmHg) and AML (<24mmHg)
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. The latter study, categorized hyposensitivity when pain thresholds exceeded 38 mmHg
Colonic transit study
Colonic motility is a critical process underlying the major functions of the large bowel.
Disorders of colonic motility typically present with constipation or diarrhea.
Measurement of colonic transit time is useful in evaluating colonic motility, and allows both the severity of the problem and the response to therapy to be assessed. 
Genetic / epigenetic analysis
IBS frequently clusters within families, thus suggesting a degree of heritability [85] [86] [87] .
Furthermore, twin studies have demonstrated that the genetic heritability is in the order of 22-57% and the reported concordance rates for IBS differ between monozygotic and dizygotic twins, with 33% concordance in the former and 13% in the latter To date, the largest population based IBS GWAS study has examined more than 500
patients with an IBS-like phenotype, in comparison to 5000 matched controls from a twin registry in the discovery sample and replicated these findings in a further cohort of approximately 3500 IBS patients and controls Therefore, in order to address these methodological deficiencies, an international consortium needs to be established to collect blood samples suitable for genetic and epigenetic analysis, patient information and functional data from large numbers of patients (see www.GENIEUR.eu). Such an approach will aid in redressing many of the issues regarding sample size that have limited the interpretation of previous studies.
Microbiota analysis
As a consequence of advances in high throughput DNA sequencing over the recent past, quantification of the human microbiota has become feasible
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. Given the marked interaction between the gut microbiota and the structure and function of the gastrointestinal tract, it is not surprising that the microbiota has been the subject of intense research interest within IBS. A number of research groups have used cultureindependent techniques to examine the role of the microbiota in different IBS subtypes
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. Hitherto, the sample sizes of the studied patient cohorts have been relatively small, in addition to a lack of uniformity regarding sampling methods and the collection of phenotypical data between studies, thereby rendering direct comparison a challenge.
By standardizing the faecal sample collection (see www.GENIEUR.eu) and the information relevant for microbiota analysis (diet, antibiotic use, psychological trait and state, etc.), more robust data will be obtained and the interaction with genetic factors of the host can be studied in great detail.
Colonic biopsy sampling
Colonic biopsies can be used to monitor inflammatory events in the intestine as well as changes in neuronal plasticity, neurotransmitter alterations and intestinal permeability. In addition, differential gene expression (mRNAs, ncRNAs, miRNAs), 
Implementation of large databases: chances and challenges

Organisational issues
The development and implementation of a pan-European IBS sample collection and database poses considerable challenges to all partners involved. Numerous obstacles, such a local ethical regulations, validation and translation of questionnaires, harmonization, standardization, best practices, standard operation procedures (SOPs), data protection and intellectual property rights all have to be taken into account. Professional electronic custom made databases are costly, not only when design and development is concerned, but also when considering on-going
maintenance. An identical argument holds true for the storage of collected samples.
The costs to purchase a professional system easily rises up to €50,000. Clearly, funding should be obtained to finance such tools as not all partners may have the required resources. Of note, funding agencies are currently not enthusiastic to finance such types of enterprises, seriously hampering initiatives aiming to create a multicentre international tissue bank. Nevertheless, ideally, all information on collected tissue, patient information, location of storage, test results, etc. should be hosted on a central server equipped with an appropriate firewall fulfilling security standards. Data and material use at particular sites will be regulated by material transfer agreements (MTAs) between partners and access to data will be given based on 'need to know' basis for the particular project.
Local ethics & legal implications
A substantial hurdle in international sample collection and database implementation are the variable standards at national/local medical ethical committees (METCs 
Translation into different languages
When setting up a large pan-European or international sample collection and database, especially related to questionnaires dealing with patient symptomatology and psychological aspects, language considerations are centrally important. Whereas papers published in peer-reviewed journals usually report data from questionnaires that are available and mostly validated in English, these questionnaires are usually not translated in other languages in a validated manner. Translation is a process that has to incorporate local culture, religion, language-specifics and interpretation 
Conclusion
Despite the challenges discussed above, implementation of a large European or international biobank and database offers valuable opportunities and is fundamental to address many of the knowledge gaps that exist within the field. The necessity of unifying and harmonizing approaches across Europe, and ideally the world, allows greater data compatibility, and larger databases across countries and will improves the quality of multi-centres trials and ultimately patient outcomes.
